Evidence map›Paper›PMID 35794586›Full record

ArticleBMC medical informatics and decision making2022

Use of machine learning to identify patients at risk of sub-optimal adherence: study based on real-world data from 10,929 children using a connected auto-injector device.

Amalia Spataru, Paula van Dommelen, Lilian Arnaud, Quentin Le Masne, Silvia Quarteroni, Ekaterina Koledova

Open access · goldAbstract read
In one paragraph

Article in BMC medical informatics and decision making, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Precision diagnostics in children.Cambridge prisms. Precision medicine · 2023
    Review
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Amalia SpataruSwiss Data Science Center, ETH Zürich and EPFL, Zürich, Switzerland.
Paula van DommelenThe Netherlands Organization for Applied Scientific Research TNO, P.O. Box 2215, 2301 CE, Leiden, The Netherlands. paula.vandommelen@tno.nl.ORCID 0000-0001-5546-6244
Lilian ArnaudConnected Health and Devices, Global Healthcare Operations, Ares Trading S.A., An Affiliate of Merck KGaA, Eysins, Switzerland.
Quentin Le MasneConnected Health and Devices, Global Healthcare Operations, Ares Trading S.A., An Affiliate of Merck KGaA, Eysins, Switzerland.
Silvia QuarteroniSwiss Data Science Center, ETH Zürich and EPFL, Zürich, Switzerland.
Ekaterina KoledovaGlobal Medical Affairs Cardiometabolic & Endocrinology, Merck Healthcare KGaA, Darmstadt, Germany.
ETH Zurich · CHMerck Serono (Switzerland) · CHMerck (Germany) · DENetherlands Organisation for Applied Scientific Research · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOur aim was to develop a machine learning model, using real-world data captured from a connected auto-injector device and from early indicators from the first 3 months of treatment, to predict sub-optimal adherence to recombinant human growth hormone (r-hGH) in patients with growth disorders.

methodsAdherence to r-hGH treatment was assessed in children (aged < 18 years) who started using a connected auto-injector device (easypod™), and transmitted injection data for ≥ 12 months. Adherence in the following 3, 6, or 9 months after treatment start was categorized as optimal (≥ 85%) versus sub-optimal (< 85%). Logistic regression and tree-based models were applied.

resultsData from 10,929 children showed that a random forest model with mean and standard deviation of adherence over the first 3 months, infrequent transmission of data, not changing certain comfort settings, and starting treatment at an older age was important in predicting the risk of sub-optimal adherence in the following 3, 6, or 9 months. Sensitivities ranged between 0.72 and 0.77, and specificities between 0.80 and 0.81.

conclusionsTo the authors' knowledge, this is the first attempt to integrate a machine learning model into a digital health ecosystem to help healthcare providers to identify patients at risk of sub-optimal adherence to r-hGH in the following 3, 6, or 9 months. This information, together with patient-specific indicators of sub-optimal adherence, can be used to provide support to at-risk patients and their caregivers to achieve optimal adherence and, subsequently, improve clinical outcomes.

Indexed as

EcosystemHuman Growth HormoneMachine LearningMedication AdherenceChildGrowth DisordersHealth PersonnelHumansHuman Growth HormoneAdherenceAuto-injectorConnected deviceDigital healthIndicatorMachine learningRecombinant human growth hormone

Identifiers

PMID35794586
PMCPMC9261072
OpenAlexW4284893356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.